Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti-vascular endothelial growth factor (VEGF)-based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusions: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF-based strategies, warranting prospective validation.
Amaç: Hastanemiz Tıbbi Onkoloji Servisi’ne yatan 65 yaş ve üzeri hastaların klinik özellikleri hakkın-da bilgi edinmeyi hedefliyoruz. Ayrıca, giderek yaşlanan nüfus göz önünde bulundurularak, ileriye dö-nük bakım koşullarının iyileştirilmesine, bakım merkezleri ile sağlık personeli sayısının planlanmasına katkı sağlamayı amaçlıyoruz.Yöntem: Tıbbi Onkoloji Servisi’ne Mart 2024-Mart 2025 tarihleri arasında yatan 65 yaş ve üzeri hasta-lar geçmişe dönük olarak değerlendirilmiştir. Hastaların cinsiyetleri, yaşları, tanıları, yatış nedenleri, yatış süreleri, yoğun bakıma gitme ve mortalite oranları incelenmiştir.Bulgular: 159 hastamızın 91’i (%57) erkek, 68’i (%43) kadındır. Erkeklerin yaş ortanca değeri 71(65-86), kadınların 71(59-89)’dir. Hastalarımızda en çok görülen kanser 53 hasta ile akciğer kanseridir. En sık hastaneye yatış sebebi 76 hasta ile tetkik, kemoterapi ve kan replasmanı nedenli iken, 2. olarak 16 hasta ile beslenme bozukluğu, 3. neden ise 14 hasta ile nefes darlığıdır. Erkek hastalar ile kadın hastalar arasında (p=0.760); erken ve orta yaşlılar arasında (p=0.569) ve orta ile ileri yaşlı hastalar arasında has-tane yatış süresi açısından anlamlı farklılık saptanmamıştır(p=0.580).Sonuç: Geriatrik hasta nüfusu geçmişe oranla artmış olup, bu durum yaşlı kanser hastalarının sayısında da artışa neden olacaktır. Bununla beraber hastalarda meydana gelen semptomlar nedeni ile gerekli ihti-yaçlar önem kazanmaktadır. Geriatrik onkoloji hastalarının bakım şartlarının iyileştirilmesi ve geleceğe dönük gerekli planlamaların yapılması gerekmektedir. Bu doğrultuda geriatrik onkoloji biliminin yol göstericiliği ile gerekli düzenlemeler yapılmalıdır.
20 August 2025 in Spor ve Performans Araştırmaları Dergisi
This study was conducted to determine the effects of calisthenic exercises on certain physical parameters and muscle strength in women who have undergone mastectomy surgery. A total of 30 women, aged between 40 and 60 years, who were receiving post-mastectomy treatment at Çanakkale Onsekiz Mart University Training and Research Hospital, voluntarily participated in the study. Participants were selected using a simple random sampling method. Individuals deemed eligible for measurements by a specialist oncologist were included in the study. Institutional permission and ethical approval were obtained from the Faculty of Medicine at Çanakkale Onsekiz Mart University. The participants’ ages were determined based on official identification. Measurements included height, body weight, body fat percentage, circumference measurements, handgrip strength, leg and back strength. The results were presented as arithmetic means (x̄) and standard deviations (sd). Independent samples t-test was used to determine differences between groups. The level of significance was set at p
Kanser hastalarında yaşam kalitesini ve tedaviden görülen faydayı artıran en önemli faktörlerden biri beslenmedir. Hastalarda kanserin cinsi ve uygulanan tedavi ile tedavi sonucunda oluşan semptomlardan dolayı beslenme sorunları yaşanabilir. Bu da malnütrisyona neden olmaktadır
Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti–vascular endothelial growth factor (VEGF)–based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusion: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF–based strategies, warranting prospective validation.